Indivior Raises Guidance After Strong Q1, Boosts Buybacks
Indivior lifted full-year revenue and EBITDA forecasts following 19% YoY Q1 growth and a $175 million share repurchase plan. Indivior Pharmaceuticals raised its 2026 guidance to $1.215–$1.285 billion in net revenue and $620–$660 million in adjusted EBITDA after Q1 results.